Walsh currently serves as the executive vice president and chief financial officer at Catalent, a role he assumed in 2008. Prior to joining Catalent, he was president, chief financial officer, and acting chief executive officer at Escala Group, Inc.
Walsh is a CFA charterholder who received an MBA from Cornell University, SC Johnson Graduate School of Management, and a BS in Chemical Engineering from Cornell University, College of Engineering.
Allergan is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices, and biologic products for patients around the world.
The company markets a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer